Kyongbo Pharm said Tuesday it recently obtained approval from the Ministry of Food and Drug Safety for DPP-4 antidiabetic drugs Vilda Tab. and Vildamet Tab.

Four products got the marketing approval – one monotherapy using vildagliptin as the main ingredient and three doses of Vilda Tab. plus metformin Vildamet Tab. (50/500mg, 50/850mg, and 50/1000mg).

Using a new salt (nitrate) in both products, Kyongbo Pharm improved the hygroscopicity, a characteristic of vildagliptin, and improved its purity so that it does not change in high temperature and high humidity.

Changing the existing aluminum PTP packaging to bottle packaging improved dispensing convenience for pharmacists and drug compliance for patients.

“We got approval for all doses so that doctors can prescribe Vilda Tab. and Vildamet Tab. according to the symptoms of diabetic patients. In addition, we improved hygroscopicity and stability using our technology,” an official at Kyongbo Pharm said.

The official added that the company would provide broad treatment options with Vilda Tab. and Vildamet Tab. for physicians and diabetic patients.